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ABSTRACT* 
Background: Management of chronic disease has 
become an increasing challenge to the National Health 
Service in the United Kingdom. The introduction of 
supplementary prescribing was seen as a possible 
mechanism to address the needs of this patient group. 
Individuals with mental illness were considered particularly 
suitable for management in this way.  
Objective: To explore the views and experiences of 
patients with mental illness on being managed by a 
pharmacist supplementary prescriber in a secondary care 
outpatient setting.  
Methods: A study of patient experiences utilising semi-
structured interviews and self-completion diaries was 
adopted. Eleven patients participated in the study. Data 
were analysed utilising code and retrieve, and content 
analysis respectively.  
Results: Patients valued the increased accessibility to, 
and continuity of, their prescriber compared with their 
experience of other healthcare professionals. Patients 
reported they were able to trust the pharmacist’s 
knowledge of medication, were provided with sufficient 
information regarding reasons for treatment and side 
effects, and felt that they had an active role in decisions 
concerning their healthcare.  
Conclusions: This exploratory study showed that patients 
had positive views of being managed by a supplementary 
prescriber. However, it should be noted that the number of 
participants was small. It is therefore important that further, 
more wide ranging research is conducted to evaluate 
pharmacist prescribing within mental health settings. 
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INTRODUCTION 
Management of chronic disease has become an 
increasing challenge to the National Health Service 
(NHS) in the United Kingdom (UK) with an 
estimated 17.5 million adults suffering from long-
term conditions.1 It has been reported that these 
patients account for approximately 80% of general 
practitioner (GP) consultations and occupy 60% of 
hospital beds.1 The introduction of non-medical 
prescribing was seen as a possible mechanism to 
address the needs of this patient group by the 
Department of Health in the UK.1 Predicted benefits 
included enhanced access to healthcare, improved 
management of medication and improved patient 
safety.2 Non-medical prescribing by pharmacists 
has been implemented internationally (including in 
the USA, Australia and Canada); however, the 
models adopted within each country differ.3 
Supplementary prescribing in the UK allows 
appropriately trained health professionals (such as 
pharmacists and nurses) to manage patients under 
the direction of a clinical management plan. A 
summary of the roles and responsibilities of a 
supplementary prescriber in the UK can be seen in 
Table 1. In the mental health setting, this 
development was supported by the document “New 
ways of working for psychiatrists” which raised the 
profile of mental health pharmacists and pharmacist 
non-medical prescribing by advocating appropriate 
delegation within the multidisciplinary team.4 The 
UK Psychiatric Pharmacists Group and College of 
Mental Health Pharmacists and the Department of 
Health identified that individuals with mental illness 
were considered particularly suitable for 
management by non-medical prescribers (NMP).5,6 
The College of Mental Health Pharmacists indicated 
that only specialist mental health pharmacists would 
be suitable to undertake this role due to their 
qualifications and specific knowledge of this 
therapeutic area.6 
Table 1. Supplementary prescriber roles and 
responsibilities. 
 Supplementary prescriber works in partnership with 
an independent prescriber (doctor) to manage care 
of patient  
 Diagnosis undertaken by independent prescriber 
(Doctor) 
 Patient-specific clinical management plan is 
developed and utilised for each patient to set out in 
detail what the supplementary prescriber can 
prescribe and for which indications  
 Partnership and shared responsibility for patient 
management  
 Able to prescribe any medicine (listed on clinical 
management plan) 
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Supplementary prescribing is a partnership between 
a pharmacist supplementary prescriber, patient and 
independent prescriber.5 The manner in which this 
partnership works has been recognised as a crucial 
factor in determining the effectiveness of the 
service. However, few studies have focussed on the 
views of the service user.7,8 Importantly, the 
Department of Health indicated that the opinions of 
service users should be sought in order to improve 
care and facilitate a “patient led NHS”.9 Published 
studies in the UK have shown patients to be 
generally satisfied with pharmacist supplementary 
prescribing but these have not explored the views of 
those with mental illness.10-13 Previous research in 
secondary care with patients diagnosed with 
schizophrenia found that they were dissatisfied with 
the information provided to them about their 
medication and with their level of input into 
healthcare decisions.14 The extensive knowledge of 
the specialist pharmacist coupled with the extended 
role in the prescribing process may be a tool with 
which to address certain patient concerns and 
improve healthcare.  
The aim of this study was to explore the views and 
experiences of patients with mental illness on being 
managed by a pharmacist supplementary prescriber 
in a secondary care outpatient setting. 
 
METHODS  
Approval for the study was obtained from Dyfed 
Powys Research Ethics Committee and the 
appropriate NHS Trust Research and Development 
Office. A case study of one pharmacist prescriber 
utilising two qualitative methodologies, namely 
semi-structured interviews and self-completion 
diaries was adopted. The use of multiple methods is 
a recognised feature of a case study approach in 
order to describe the phenomenon under 
investigation.15 The pharmacist was identified 
through a known contact of the researcher as being 
an actively practising supplementary prescriber, as 
such, convenience sampling was utilised. They 
were female, with approximately 10 years clinical 
experience within the field of psychiatry.  
The supplementary prescriber worked in partnership 
with five independent prescribers, all of whom had 
given written informed consent for their patients to 
be approached as potential participants and had 
themselves been provided with a description of the 
study methodology. Reasons for referral to the 
pharmacist supplementary prescriber by the 
independent prescribers (psychiatrists) included 
management of dose titration or to provide more 
detailed guidance on medication issues. Patients 
were treated for bipolar disorder, psychosis or 
depression. All eligible patients were identified by 
the supplementary prescriber and independent 
prescriber and provided with written information 
about the study during a routine pharmacist 
supplementary prescriber consultation. Patients 
were identified and approached by the pharmacist 
over a discreet time period. Inclusion criteria for the 
study required patients to be over 18 years of age, 
have their care managed by the pharmacist 
supplementary prescriber for a minimum of two 
previous consultations, and deemed able to provide 
informed consent by their care team. Written 
informed consent was obtained prior to 
participation. Upon enrolment patient demographics 
were provided to the researcher by the pharmacist 
supplementary prescriber. The project consisted of 
three stages. All consenting patients were required 
to participate in stage 1, and were then able to 
choose whether or not to complete stages 2 or 3. A 
small financial remuneration was offered to thank 
participants for their time (GBP10 each for stages 
one and three, GBP5 for completion of stage two). 
Stage 1: Semi-structured interview following 
supplementary prescriber consultation 
Patients were interviewed by the researcher (RED) 
in private, immediately following a consultation with 
the pharmacist supplementary prescriber either 
within an out-patient clinic or hospital pharmacy 
department. The purpose of this stage was to 
encourage participants to reflect and discuss 
immediately post-consultation. A semi-structured 
interview schedule was developed (see Table 2 for 
the topic outlines), utilising open questions to allow 
patients to discuss their views freely. The interview 
schedule was piloted with the first patient and minor 
changes made. Interviews were audio-recorded with 
written consent and transcribed ad verbatim.  
Stage 2: Patient completion of diary 
Immediately following the post-consultation 
interview participants were provided with a research 
diary and were invited to use it over the following six 
weeks to record events related to their care by the 
supplementary prescriber such as further 
appointments. Diaries were utilised to allow patients 
the opportunity to record events as they happened, 
therefore reducing the need to rely upon their 
memory to such a great extent during the interview 
in stage three.16 Patients were asked to 
prospectively record the date and description of 
events related to the care provided by the 
supplementary prescriber (for example, any 
telephone calls or appointments that may have 
been held during that time). Guidance was provided 
at the front of the diary and reinforced verbally upon 
distribution. Entries did not have to be made on a 
daily basis, only when relevant events occurred. 
Participants were contacted by their preferred 
method (email or telephone) after approximately 
three weeks to allow them the opportunity to ask 
questions and then again at the end of six weeks as 
a reminder to return the completed diary.17 Entries 
served as an aide-mémoire for the final interview in 
stage three. 
Table 2. Stage 1: Post consultation topic guide. 
 Patient expectations of their appointment  
o To what degree were the expectations met 
 Patient agenda for the appointment 
 Patient: pharmacist interaction  
o Opportunity for patient to communicate their 
thoughts 
o Opportunity to ask questions  
 Length of appointment  
 Future recommendations  
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Stage 3: Post-diary interview 
Following the diary period, or after approximately six 
to eight weeks if no diary was completed, 
consenting participants attended a final face-to-face 
interview. A semi-structured interview was 
conducted; this is known as the diary: diary-
interview method.18 The focus of this stage was to 
establish patient views of on-going management by 
the supplementary prescriber (this is in contrast to 
stage one where the focus was on the most recent 
interaction, see Table 3 for the topic outlines), with 
reference to the diary entries. Interviews were held 
following a further appointment with the 
supplementary prescriber in order to minimise 
inconvenience to the participants. If this was not 
possible, a mutually agreed time and place was 
arranged. Interviews were audio-recorded with 
written consent and transcribed ad verbatim.  
Data analysis  
All data and patient information were anonymised. 
Following interview transcription, a code and 
retrieve analysis was carried out to allow the 
identification of and coding of common themes.19 
Code and retrieve involves bringing together 
sections of text with common themes, they are then 
coded or labelled. This allows the commonalities, 
differences and patterns of the interviews to be 
identified. Themes were identified inductively from 
the data. Analysis was carried out in a cyclical 
process to ensure that no codes had been missed. 
Diary entries were analysed by thematic content 
analysis20 in order to categorise the type of entries 
provided. The Qualitative Data Analysis Software 
N6 was utilised to assist in data management and 
analysis. Each stage was analysed chronologically 
as the focus of each stage was different. All 
transcribing and data analysis was carried out by 
the main researcher.  
 
RESULTS  
Thirteen of 20 patients treated by the 
supplementary prescriber during the study period 
were provided with information about the study. The 
remaining seven did not meet all of the inclusion 
criteria or were too unwell to participate (as 
determined by the pharmacist and their independent 
prescriber). Twelve patients provided consent for 
each stage. One patient who gave consent did not 
participate due to deterioration in mental state; 
therefore 11 patients participated in the study. 
Patient demographics are shown in Table 4. The 
results of each stage are presented below:  
Stage 1: Semi-structured interview following 
supplementary prescriber consultation.  
Eleven patients participated in this stage. Interviews 
lasted a mean of 18 minutes. The main themes 
generated from these interviews, and discussed 
below, were: 
 The pharmacist-patient relationship  
 Comparison to other HCPs 
 Time allowed for the consultation 
All participants felt comfortable consulting with their 
pharmacist and had developed a trusting 
relationship with her. Patients stated that the 
pharmacist’s personality played a significant role in 
developing rapport, alongside her knowledge of 
their condition and treatment. The relationship was 
felt to be especially important for managing 
individuals with a mental illness: 
PT1 …you’ve got to be a certain type of 
person who can make somebody with mental 
health issues and prescribing their drugs at 
ease and be able to express how you feel. 
Participants believed that the pharmacist listened to 
what they had to say during their consultations. 
Patient 9 considered this to be a positive feature in 
comparison to their prior experiences: 
PT9 … I would say …… I felt like I was 
listened to she didn’t sort of cos sometimes in 
the past when I’ve seen maybe not her but 
like a doctor I, some of the ideas have been 
like not listened to or dismissed that sort of 
thing so I feel she listens quite well. 
As the pharmacist listened to the patients’ views 
and openly discussed treatment options, patients 
perceived any decisions to be made in partnership: 
PT5 Whereas if you say how do you feel 
about this do you want to go up [dose] do you 
want to take them [medication] off you know 
it’s not the ‘I’m the professional I’m telling you 
what to do’…..you know it’s let’s discuss this 
this together so I I think that’s the best 
approach. 
Table 3. Stage 3: Follow up topic guide. 
 Patient views on pharmacist prescribing and 
previous experiences  
 Patient’s awareness of the pharmacist’s role  
 Management of patient’s condition since seeing 
the pharmacist  
 Patient expectations of a prescribing pharmacist  
 Patient: pharmacist interaction  
o Outside of organised appointments  
 What constitutes a typical appointment  
Table 4. Patient demographics (n=11). 
 Number  
Age (years) 
18-29 
30-39 
40-49 
50+ 
 
3 
3 
3 
2 
Gender 
Male 
Female 
 
3 
8 
Diagnosis 
Bipolar disorder 
Psychosis and depression 
Depression 
 
8 
1 
2 
Co-morbidities  
      Menopausal symptoms 
      Poly-cystic ovary syndrome 
      Eating disorder 
      Psoriasis 
      Hypertension  
 
1 
1 
1 
1 
1 
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Throughout the interview participants compared the 
pharmacist’s approach to those experienced with 
GPs and psychiatrists. Positive views of the 
supplementary prescriber pharmacist were 
expressed by all. This was especially true with 
regards to the continuity of healthcare professional, 
the pharmacist’s knowledge, how they felt within the 
consultation and their involvement in any decisions 
concerning their care: 
PT7  Something that used to be a pain was 
that the doctors changed for ever and I can’t 
remember how many doctors assured me no, 
they were going to be here and then they 
went they we’re all lovely people and um ….I 
eventually got to the point where I didn’t 
actually want to invest anything in them. 
PT2  I trust what she has to say about um 
drugs more than I would a 
doctor……..because I think she’s more 
knowledgeable……… in terms of drugs and 
what they do and how they work, I think she 
knows more than a doctor would. 
Patients had increased involvement in the 
consultation, making it a more lengthy process. This 
was seen as an advantage not always experienced 
in other circumstances: 
PT7 …one of the nice things about coming in 
with a change of problem and talking to 
[pharmacist] is that we have time to go 
through it properly whereas I have a feeling if 
I go to my GP he’s watching his watch. 
Stage 2: Patient completion of diary 
Seven of the 11 participants completed diaries over 
a six week period. There were no differences in 
terms of age, gender and diagnosis between those 
who did participate compared to those who did not. 
The number of entries ranged from four to 44 and 
were categorised into broad themes. Patients 
described a range of events or thoughts related to 
the care provided by the pharmacist. No significant 
incidents occurred throughout the study for any of 
the participants. However, entries included: 
 a brief description or an arrangement of a 
consultation with the pharmacist 
PT2 Appointment with [pharmacist]. Checked 
rash, side effects and asked if I wanted to carry 
on. Had longer two month type appointment. 
 an occasion where both pharmacist and 
patient had made a joint decision regarding 
therapy 
PT5 I had an appointment with my 
pharmacist – we chatted for 30 mins about my 
mood, sleep, eating etc. It was a really good 
session, she listened to what I had to say and 
we agreed to increase the dose of my meds. 
 the pharmacist’s availability outside of the 
consultation  
PT2 [pharmacist] phoned me as she said she 
would. Explained what the doctor said and 
gave me the choice to proceed or not. 
Remembered I was at my parent’s house and 
made arrangements for tablets to be delivered 
to pharmacy nearer their house. 
 patients’ intentions to discuss particular 
issues with the pharmacist at the next 
available opportunity   
PT8 Having a very down day, will discuss 
how I feel with pharmacist next time. 
 their general views of the service 
PT8 Saw pharmacist today, all went well, 
meds have been really helping and we 
discussed all possible issues / complications 
and all is ok. Feel quite relaxed about meds 
ok to increase dosage of one of meds. 
The entries provided an insight into the patient’s 
ongoing relationship with the pharmacist and their 
subsequent communications. 
Stage 3: Post-diary interview 
Eight patients participated in the final stage of the 
study. There were no differences in terms of age, 
gender and diagnosis between those who did 
participate compared to those who did not. 
Interviews lasted a mean of 32 minutes and 
focussed on the on-going management by the 
supplementary prescriber.  
The main themes generated from these interviews, 
and discussed below, were: 
 Patient satisfaction 
 Consistency of care  
 Pharmacist accessibility 
 Pharmacist knowledge  
 The mental health patient  
The interviews in this final stage raised very similar 
issues to those discussed in stage one, where 
patients compared the care from other healthcare 
professionals to that provided by the pharmacist 
supplementary prescriber. All patients expressed 
positive views of the manner in which they were 
engaged in the decision making process and were 
satisfied with the service. They also believed the 
amount and level of information provided by the 
supplementary prescriber was appropriate:  
PT2  …like I have a lot of choices, 
[pharmacist] doesn’t tell me what to do, she 
kind of gives me choices about what I could 
do um its very kind of co-operative. 
All of these views contrasted to patients’ previous 
experiences with GPs and psychiatrists. It was 
perceived that doctors did not take their views into 
account and did not provide as much information 
within the consultation: 
PT8  It felt a little bit more interactive cos 
sometimes I did feel …. doctors they are a 
little bit more kind of you have to take it like 
this and you’re going to take it like this and 
then you’ll come back in a while and see if it’s 
all ok kind of thing whereas it was more 
progressive if you know what I mean.  
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PT4  … seems to be quite good actually 
cause she does give me a lot more 
information about the actual drugs themselves 
than the doctor ever did. So, she seems to 
know a greater variety and be a lot more up to 
date on all of them.  
As established in stage one, participants 
appreciated consulting with the same healthcare 
professional on a regular basis. This continuity gave 
the opportunity for the pharmacist to monitor their 
condition more closely, to tailor the medication to 
the individual and to allow the patient to ask 
questions and discuss their condition. 
PT9 …well one reason why I’ve stayed with 
the pharmacist for such a long time was 
because what I was finding with the 
psychiatrist, I was seeing him not very 
frequently. 
Participants found the supplementary prescriber 
more accessible than a psychiatrist and were 
regularly given the option of contacting the 
supplementary prescriber beyond the immediate 
face-to-face consultation, either via email or 
telephone: 
PT5 …mmm and I think also I can get hold of 
her ….. and I will be able to speak to her 
directly whereas with a psychiatrist you would 
struggle to do that or they’d probably leave a 
message and they might ring you in three 
days time.  
Participants recognised the pharmacist’s high level 
of knowledge regarding their medication. This 
awareness contributed to patients’ confidence in the 
pharmacist’s role:  
PT1  And I said I’m more than happy for her 
to do that because I trust her and her 
knowledge, she’s a pharmacist. 
Finally, some participants believed that the 
approach of healthcare professionals to patients 
with mental illness should be different to those with 
physical illness. A suggested reason for this was the 
sensitive nature of the conditions and that 
medication is often approached on a ‘trial and error’ 
or ‘guinea pig’ basis. Importantly, patients cannot 
take a ‘magic bullet’ (Patient 8) to cure their 
condition and medication therefore needs to be 
tailored to the individual:  
PT5 … in terms of say the GP doing it like I 
would prefer to come here and see 
[pharmacist] than do it with the GP because 
[pharmacist] understands all the mental health 
stuff and some GP’s they don’t really get it or 
they don’t believe in it or whatever. 
All patients in this exploratory study expressed 
positive views on the service. The only negative 
comments related to the delay in collecting their 
medication from the pharmacy on a few occasions. 
However, this was associated with the procedures 
of dispensing and supplying the medication rather 
than the supplementary prescriber more specifically.  
 
DISCUSSION 
This exploratory study elicited the opinions of 
patients with mental illness on their management by 
a pharmacist supplementary prescriber. Within this 
particular setting the pharmacist received referrals 
from all five of the independent prescribers who 
agreed to their patients being included in the study. 
Reasons for referral included initiation of medication 
requiring close monitoring and treatment of patients 
with complex pharmaceutical needs. The differing 
independent prescribers and varied reasons for 
referral allowed a range of subjects to be included. 
There was a degree of attrition as not all patients 
participated in all stages. However, there were no 
differences in terms of age, gender and diagnosis 
between those who did participate compared to 
those who did not. The views were positive, 
consistent with findings from other small scale 
studies conducted within the UK.11,21,22 Perceived 
patient benefits of pharmacist prescribing have also 
been reported by supplementary prescribers 
themselves and other stakeholders.12,23-26  
Patients felt that they had developed a meaningful 
and trusting relationship with their supplementary 
prescriber over time. The importance of having such 
a close association has been highlighted by the 
National Institute for Health and Clinical Excellence 
(NICE) in their guidelines to treat bipolar disorder. It 
is recommended that healthcare professionals 
”establish and maintain collaborative relationships 
with patients …… be respectful of the patient’s 
knowledge and experience of the illness”.27 A 
similar view was expressed by one of the 
participants who felt that managing patients with 
mental illness required a different approach 
compared to those with physical illness. It was 
perceived that the pharmacist created a ‘friendly 
and relaxed’ atmosphere within the consultation and 
that they were easier to talk to than the psychiatrist. 
The importance of positive relationships between 
mental health patients and community pharmacy 
staff was highlighted by Knox and colleagues.28 
Similarly, participants in other studies believed their 
pharmacist prescriber displayed an interest in them 
as a ‘person’ rather than as an illness and provided 
more time to discuss their health-related issues.11,22 
This research was largely conducted in the general 
practice or community pharmacy; therefore the 
prescribing role may have been somewhat different 
to the current study where the prescribing role was 
carried out in a secondary care out-patient setting. 
However, this study does provide further evidence 
of a patient focused interaction. In addition to the 
approach of the supplementary prescriber, other 
factors contributed to the development of this 
rapport, namely the time allowed for the 
consultation and continuity of care.  
In contrast to their prior experiences with other 
healthcare professionals, patients in this study 
valued the increased accessibility to their 
prescriber. This included an ability to contact the 
supplementary prescriber more easily than they 
would a doctor.11,12 Furthermore, it was highlighted 
by one patient that when attending appointments 
with rotational junior medical staff it was necessary 
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to repeat their “story” on each occasion. The 
continuity achieved through management by the 
same supplementary prescriber allowed for 
discussion of issues that were important to the 
patient and relevant to their current treatment. All of 
these benefits were identified at the inception of 
supplementary prescribing alongside the main focus 
to improve patient safety.2,5 The pharmacist 
supplementary prescriber allocated 30 minutes for 
each appointment, although in practice this was 
frequently extended according to the patients’ 
individual requirements. This was in contrast to the 
strict ten minute appointments patients experienced 
with their GP or 20-30 minutes with their 
independent prescriber. Having more time available 
for appointments meant that areas outside the 
illness could be discussed increasing understanding 
between patient and healthcare professional.  
Research conducted in Australia has shown that 
mental health patients value good quality services 
within pharmacy, including respecting their 
privacy.29,30 However, patients with mental illness 
have previously expressed views that they receive 
insufficient information about medication and do not 
feel involved in healthcare decisions to the extent 
they would wish.14,31 It has been previously reported 
that patients took antipsychotic medication because 
they ‘were told to’ despite experiencing side 
effects.14 However, in the context of the present 
study patients were able to trust the pharmacist’s 
knowledge of medication, and were provided with 
sufficient information. This is consistent with the 
initial reasons for referral to the supplementary 
prescriber, as a pharmacist might be considered the 
most suitable healthcare professional to manage 
these aspects of patient care. Similarly, patients in 
general healthcare settings believed that pharmacist 
supplementary prescribers provided more 
medication information than their previous 
prescribers.10 All patients in the current study 
reported being actively involved with the 
supplementary prescriber in treatment decisions 
which was considered positive compared to their 
previous experiences with other healthcare 
professionals. On all occasions their current care 
programme was perceived to be more patient 
focussed. Importantly, whether a consultation is 
‘patient-centred’32 can impact on patient outcomes 
and medication adherence.33   
Limitations 
In this exploratory study the views of eleven patients 
managed by a pharmacist supplementary prescriber 
working within general adult psychiatry were 
investigated using a case study approach. The 
single pharmacist and small number of patients are 
limitations of the study. As seen from stage one 
(interview) data, patients identified the personality of 
the pharmacist to be a key factor in determining 
their satisfaction with the service. The manner in 
which other pharmacists would therefore interact 
with the participants could be significantly different 
and therefore limits the generalisability of the 
results. In addition, the patients were largely female 
with bipolar disorder. Furthermore, the results are 
only valid for this particular setting and cannot be 
extrapolated to other areas either within mental 
health, such as old-age or addiction psychiatry, or to 
other healthcare fields. The aim of this study 
however, was not to generalise. The manner in 
which patients were identified and the requirement 
for each patient to have seen the supplementary 
prescriber for a minimum of two consultations may 
have introduced an element of selection bias. 
Patients with positive views or those considered to 
be especially motivated could have been identified 
for inclusion by the supplementary or independent 
prescriber, whilst dissatisfied patients may have 
withdrawn from the supplementary prescriber 
service after the first consultation.  These limitations 
may have been compounded by the small sample 
size. However, other studies exploring patient views 
on non-medical prescribing have been on a similar 
small scale.10,12 Prior to participation in the study, 
the supplementary prescriber was aware that stage 
one involved an in-depth discussion of the most 
recent pharmacist-patient consultation. This may 
have influenced the way in which the pharmacist 
approached that specific interaction. It was also 
noted that although the foci of stages one and three 
were different (immediate response to the 
supplementary prescriber consultation versus 
longer term views of management respectively) 
patients’ responses during the interviews generated 
similar themes. Lastly, the data analysis was 
conducted by only one researcher which could have 
introduced some bias into the study. However, the 
identified themes were confirmed by the other 
researchers. Nevertheless, the methods employed 
in this exploratory study were effective in obtaining 
data from this patient group. 
 
CONCLUSIONS 
In conclusion, this study has utilised both interviews 
and diaries in a novel way to explore the views of 
patients with mental illness who are being treated 
by a pharmacist supplementary prescriber. All 
participants expressed positive views of the service 
provided by their supplementary prescriber which 
highlights the ongoing importance of this ever 
evolving role of the pharmacist within a mental 
health setting. Aspects found to be of benefit 
included increased access to and continuity of 
healthcare professional and a more active role for 
patients in decisions concerning their healthcare. All 
of these positive attributes of non-medical 
prescribing were anticipated at the inception of this 
relatively recent initiative by the Department of 
Health2 and it is encouraging to see that they have 
been realised albeit in this small scale study. It is 
important, however, that further, research is carried 
out to evaluate pharmacist prescribing within the 
mental health setting such as exploring the views of 
both supplementary and independent prescribers on 
the service and recruiting larger numbers of patients 
who are treated by a variety of prescribers. 
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ESTUDIO EXPLORATORIO DE LA 
EXPERIENCIA DE LOS PACIENTES SOBRE LA 
PRESCRIPCIÓN FARMACÉUTICA 
SUPLEMENTARIA EN UNA CLÍNICA 
SECUNDARIA DE SALID MENTAL 
  
 
RESUMEN 
Antecedentes: El manejo de las enfermedades crónicas 
se ha convertido en un reto para el Sistema Nacional de 
Salud del Reino Unido. La introducción dela prescripción 
suplementaria fue vista como un mecanismo para 
afrontar las necesidades de este grupo de pacientes. Los 
individuos con problemas de salud mental fueron 
considerados particularmente apropiados para teste tipo 
de manejo. 
Objetivo: Explorar las visiones y experiencias de los 
pacientes con salud mental al ser manejados por un 
farmacéutico prescriptor suplementario en una clínica 
ambulatoria de cuidaos secundarios. 
Métodos: Se adoptó un estudio de las experiencias de los 
pacientes utilizando entrevistas semiestructuradas y 
diarios auto-cumplimentados. Once pacientes 
participaron en el estudio. Los datos se analizaron usando 
codificación y recuperación, y un análisis de contenido 
respectivamente. 
Resultados: Los pacientes valorizaron el aumento de 
accesibilidad y la continuidad de su prescriptor 
comparado con otros profesionales de la salud. Los 
pacientes comunicaron que eran capaces de confiar en los 
conocimientos sobre medicación del farmacéutico, que 
les proporcionaba con suficiente información sobre los 
motivos de su tratamiento y efectos adversos, y sentían 
que tenían un papel activo en las decisiones sobre su 
salud. 
Concusiones: Este estudio exploratorio mostró que los 
pacientes tenían visiones positivas al ser manejados por 
un prescriptor suplementario. Sin embargo, debe 
reconocerse que el número de participantes fue pequeño. 
Por ello es importante que se realice más investigación y 
más amplia para evaluar la prescripción farmacéutica en 
las clínicas de salud mental. 
 
Palabras clave: Farmacéuticos; Prescripciones de 
Medicamentos; Trastornos Mentales; Actitud Frente a la 
Salud; Rol Profesional; Reino Unido 
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